Bone and soft tissue sarcomas represent about 7-12% of all pediatric cancer and are a heterogeneous group of tumors arising in connective tissues embryologically derived from the mesenchyme. For some of these tumors relapse and mortality rates are still significantly high. Therefore, further studies are needed to better understand pathogenetic processes underlying sarcomas to offer new and more effective treatments. Next generation sequencing (NGS) has opened new frontiers for cancer research allowing to identify somatic or constitutional mutations known or yet unknown with the aim to better understand carcinogenesis. The establishment of the genomic profile of the tumor could also help clinicians to personalize patients treatment based on their genetic and molecular alterations.
Study Type
OBSERVATIONAL
Enrollment
120
biopsy
AOU Città della Salute e della Scienza di Torino - Presidio Infantile Regina Margherita
Torino, Turin, Italy
RECRUITINGIstituto Ortopedico Rizzoli
Bologna, Italy
RECRUITINGPoliclinico S.Orsola-Malpighi
Bologna, Italy
RECRUITINGAzienda ospedaliero-universitaria Meyer
Florence, Italy
RECRUITINGIstituto Giannina Gaslini
Genova, Italy
RECRUITINGIstituto Nazionale Tumori
Milan, Italy
RECRUITINGPresidio Ospedaliero Gaetano Pini | ASST Pini-CTO
Milan, Italy
SUSPENDEDFondazione I.R.C.C.S. Policlinico San Matteo
Pavia, Italy
RECRUITINGIstituti fisioterapici Ospitalieri - Istituto Tumori Regina Elena e Istituto Dermatologico San Gallicano
Roma, Italy
ACTIVE_NOT_RECRUITINGIRCCS materno infantile Burlo Garofolo
Trieste, Italy
RECRUITINGevaluate the genomic profiles of osteosarcoma, Ewing sarcoma and Synovial Sarcoma tumor samples in pediatric, adolescents and young adult patients at the time of diagnosis or relapse/progression
Time frame: 2018-2021
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.